Stay updated on Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Sign up to get notified when there's something new on the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.

Latest updates to the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedAdded the MeSH term Malignant fibrous histiocytoma to the study's indexing terms.SummaryDifference0.1%

- Check19 days agoChange DetectedRevision: v3.5.0 is now displayed, replacing the previous Revision: v3.4.3.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedRevision: v3.4.3 added; Revision: v3.4.2 removed.SummaryDifference0.1%

- Check55 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no study content or eligibility details were altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedRevision: v3.4.0 updated to v3.4.1 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check76 days agoChange DetectedGlossary controls (Show glossary / Hide glossary) were added, and data fields were updated or renamed (Results First Posted, Last Update Posted, Last Update Submitted that Met QC Criteria). The labels 'Results First Posted (Estimated)' and 'No FEAR Act data' were removed, and the revision updated to v3.4.0.SummaryDifference0.4%

Stay in the know with updates to Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.